Delavirdine Mesylate



Delavirdine Mesylate





(dell ah vur’ den)

Rescriptor

PREGNANCY CATEGORY C


Drug Classes

Antiviral

Nonnucleoside reverse transcriptase inhibitor


Therapeutic Actions

Non-nucleoside inhibitor of HIV reverse transcriptase; binds directly to HIV’s reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities.


Indications



  • Treatment of HIV-1 infection in combination with other appropriate retroviral drugs when therapy is warranted; not intended as a monotherapy because resistant virus emerges rapidly



Available Forms

Tablets—100, 200 mg



Dosages

Adults and patients older than 16 yr

400 mg PO tid used in combination with appropriate antiretroviral drugs.

Pediatric patients

Not recommended for patients younger than 16 yr.


Pharmacokinetics















Route Onset Peak
Oral Rapid 1 hr

Metabolism: Hepatic; T1/2: 2–11 hr

Distribution: May cross placenta; may enter breast milk

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 20, 2016 | Posted by in NURSING | Comments Off on Delavirdine Mesylate

Full access? Get Clinical Tree

Get Clinical Tree app for offline access